Selective ITK Inhibition for Th1 Activity Without Broad T-Cell Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapeutic modulation of Th responses without affecting overall T-dependent immunity, as ITK inhibition is required to treat diseases influenced by Th responses, including cancer, autoimmune diseases, and allergies.
Innovation Solution
Administering ITK inhibitors, such as CPI-818, selectively targeting ITK with at least 50-fold greater selectivity than resting lymphocyte kinase, to increase Th1 activity by increasing Th1+ T cells, reducing Th2+ cells, and inhibiting Th2 cytokines, thereby treating cancer, autoimmune diseases, and allergies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If ITK inhibition is used to treat diseases influenced by Th responses, then Th2 responses are reduced, but overall T-dependent immunity is affected
Solution Approach 1:
The patent applies local quality by designing an ITK inhibitor that selectively targets ITK-expressing cells (Th2 cells, eosinophils, ILC2s) while sparing ITK-negative cells and pathways. This selective inhibition reduces Th2 responses in specific disease contexts without broadly suppressing overall T-dependent immunity, as the inhibitor does not affect RLK or other kinases involved in general T cell function.
Solution Approach 2:
The patent employs parameter changes by optimizing the inhibitor's selectivity parameter (50-fold selectivity for ITK over RLK) and dosing parameters to achieve therapeutic effects on Th2 responses while maintaining adequate T-dependent immunity. The selective inhibition parameter allows differentiation between pathogenic Th2 responses and protective T cell responses.
2Quantity of substance
If ITK inhibitors are administered to increase Th1 activity, then Th1+ T cells increase, but Th2 cytokine production is suppressed
Solution Approach 1:
The patent applies inversion by using ITK inhibition to achieve the opposite effect of what is traditionally expected from T cell activation. Instead of activating both Th1 and Th2 responses through general T cell stimulation, the inhibitor blocks ITK-mediated Th2 differentiation while permitting alternative Th1 differentiation pathways, thereby inverting the typical activation outcome to favor Th1 responses.
3Adaptability or versatility
If selective ITK inhibition is used to modulate Th responses, then therapeutic benefits are achieved, but selectivity between ITK and RLK must be maintained
Solution Approach 1:
The patent applies local quality by designing the ITK inhibitor with specific molecular characteristics that confer selectivity for ITK over RLK. The inhibitor's structure is optimized to interact with ITK-specific binding pockets while avoiding RLK, achieving therapeutic Th response modulation without off-target effects on RLK-dependent pathways.
Solution Approach 2:
The patent employs parameter changes by optimizing the selectivity parameter (achieving at least 50-fold selectivity for ITK over RLK) through molecular design and screening. This selectivity parameter is critical for achieving therapeutic benefits while avoiding unwanted suppression of RLK-dependent T cell functions.
Data Source
AI summary
The disclosure provides, inter alia, pharmaceutical compositions comprising IL-2-inducible T-cell kinase (ITK) inhibitors and methods to increase Th1 cell activity, treat cancer, treat autoimmune diseases, treat allergies, and reverse T cell exhaustion by administering to patients effective amounts of IL-2-inducible T-cell kinase (ITK) inhibitors.